Cargando…

Population-Based Monitoring of Emerging HIV-1 Drug Resistance on Antiretroviral Therapy and Associated Factors in a Sentinel Site in Cameroon: Low Levels of Resistance but Poor Programmatic Performance

BACKGROUND: Scale-up of antiretroviral therapy (ART) in resource-limited settings has drastically reduced HIV-related morbidity and mortality. However, challenges in long-term ART, adherence and HIV drug resistance (HIVDR) itself, require monitoring to limit HIVDR emergence among ART-experienced pop...

Descripción completa

Detalles Bibliográficos
Autores principales: Billong, Serge C., Fokam, Joseph, Aghokeng, Avelin F., Milenge, Pascal, Kembou, Etienne, Abessouguie, Ibile, Meva’a-Onglene, Flore Beatrice, Bissek, Anne C. Zoung-Kanyi., Colizzi, Vittorio, Mpoudi, Eitel N., Elat, Jean-Bosco N., Shiro, Koulla S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753336/
https://www.ncbi.nlm.nih.gov/pubmed/23991142
http://dx.doi.org/10.1371/journal.pone.0072680
_version_ 1782281817981714432
author Billong, Serge C.
Fokam, Joseph
Aghokeng, Avelin F.
Milenge, Pascal
Kembou, Etienne
Abessouguie, Ibile
Meva’a-Onglene, Flore Beatrice
Bissek, Anne C. Zoung-Kanyi.
Colizzi, Vittorio
Mpoudi, Eitel N.
Elat, Jean-Bosco N.
Shiro, Koulla S.
author_facet Billong, Serge C.
Fokam, Joseph
Aghokeng, Avelin F.
Milenge, Pascal
Kembou, Etienne
Abessouguie, Ibile
Meva’a-Onglene, Flore Beatrice
Bissek, Anne C. Zoung-Kanyi.
Colizzi, Vittorio
Mpoudi, Eitel N.
Elat, Jean-Bosco N.
Shiro, Koulla S.
author_sort Billong, Serge C.
collection PubMed
description BACKGROUND: Scale-up of antiretroviral therapy (ART) in resource-limited settings has drastically reduced HIV-related morbidity and mortality. However, challenges in long-term ART, adherence and HIV drug resistance (HIVDR) itself, require monitoring to limit HIVDR emergence among ART-experienced populations, in order to ensure regimen efficacy. METHODS: A longitudinal study was conducted from 2009–2011 in a cohort of 141 HIV-infected adult patients (aged >21) at the national social insurance centre hospital in Yaounde, Cameroon. As per-WHO HIVDR protocol, HIV-1 protease-reverse transcriptase genotyping was performed at baseline and at endpoint (12 months) on first-line ART using ViroSeq™ Genotyping kit. RESULTS: At baseline, a prevalence of 3.6% (5/139) HIVDR was observed [protease inhibitors M46I (1/5), G73A (1/5), L90LM (1/5); nucleoside reverse transcriptase inhibitors: M184V (1/5), T215F (1/5); non-nucleoside reverse transcriptase inhibitors: K103N (1/5), Y181Y/C (2/5), M230ML (1/5)]. At endpoint, 54.0% (76) patients were followed-up, 9.2% (13) died, and 3.5% (5) transferred, 38.5% (47) lost to follow-up (LTFU). 69.7% (53/76) of those followed-up had viremia <40 copies/ml and 90.8% (69/76) <1000 copies/ml. 4/7 patients with viremia ≥1000 copies/ml harbored HIVDR (prevalence: 5.3%; 4/76), with M184V/I (4/4) and K103K/N (3/4) being the most prevalent mutations. LTFU was favored by costs for consultation/laboratory tests, drug shortages, workload (physician/patient ratio: 1/180) and community disengagement. CONCLUSIONS: Low levels of HIVDR at baseline and at endpoint suggest a probable effectiveness of ART regimens used in Cameroon. However the possible high rate of HIVDR among LTFUs limited the strengths of our findings. Evaluating HIVDR among LTFU, improving adherence, task shifting, subsidizing/harmonizing costs for routine follow-up, are urgent measures to ensure an improved success of the country ART performance.
format Online
Article
Text
id pubmed-3753336
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37533362013-08-29 Population-Based Monitoring of Emerging HIV-1 Drug Resistance on Antiretroviral Therapy and Associated Factors in a Sentinel Site in Cameroon: Low Levels of Resistance but Poor Programmatic Performance Billong, Serge C. Fokam, Joseph Aghokeng, Avelin F. Milenge, Pascal Kembou, Etienne Abessouguie, Ibile Meva’a-Onglene, Flore Beatrice Bissek, Anne C. Zoung-Kanyi. Colizzi, Vittorio Mpoudi, Eitel N. Elat, Jean-Bosco N. Shiro, Koulla S. PLoS One Research Article BACKGROUND: Scale-up of antiretroviral therapy (ART) in resource-limited settings has drastically reduced HIV-related morbidity and mortality. However, challenges in long-term ART, adherence and HIV drug resistance (HIVDR) itself, require monitoring to limit HIVDR emergence among ART-experienced populations, in order to ensure regimen efficacy. METHODS: A longitudinal study was conducted from 2009–2011 in a cohort of 141 HIV-infected adult patients (aged >21) at the national social insurance centre hospital in Yaounde, Cameroon. As per-WHO HIVDR protocol, HIV-1 protease-reverse transcriptase genotyping was performed at baseline and at endpoint (12 months) on first-line ART using ViroSeq™ Genotyping kit. RESULTS: At baseline, a prevalence of 3.6% (5/139) HIVDR was observed [protease inhibitors M46I (1/5), G73A (1/5), L90LM (1/5); nucleoside reverse transcriptase inhibitors: M184V (1/5), T215F (1/5); non-nucleoside reverse transcriptase inhibitors: K103N (1/5), Y181Y/C (2/5), M230ML (1/5)]. At endpoint, 54.0% (76) patients were followed-up, 9.2% (13) died, and 3.5% (5) transferred, 38.5% (47) lost to follow-up (LTFU). 69.7% (53/76) of those followed-up had viremia <40 copies/ml and 90.8% (69/76) <1000 copies/ml. 4/7 patients with viremia ≥1000 copies/ml harbored HIVDR (prevalence: 5.3%; 4/76), with M184V/I (4/4) and K103K/N (3/4) being the most prevalent mutations. LTFU was favored by costs for consultation/laboratory tests, drug shortages, workload (physician/patient ratio: 1/180) and community disengagement. CONCLUSIONS: Low levels of HIVDR at baseline and at endpoint suggest a probable effectiveness of ART regimens used in Cameroon. However the possible high rate of HIVDR among LTFUs limited the strengths of our findings. Evaluating HIVDR among LTFU, improving adherence, task shifting, subsidizing/harmonizing costs for routine follow-up, are urgent measures to ensure an improved success of the country ART performance. Public Library of Science 2013-08-26 /pmc/articles/PMC3753336/ /pubmed/23991142 http://dx.doi.org/10.1371/journal.pone.0072680 Text en © 2013 Billong et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Billong, Serge C.
Fokam, Joseph
Aghokeng, Avelin F.
Milenge, Pascal
Kembou, Etienne
Abessouguie, Ibile
Meva’a-Onglene, Flore Beatrice
Bissek, Anne C. Zoung-Kanyi.
Colizzi, Vittorio
Mpoudi, Eitel N.
Elat, Jean-Bosco N.
Shiro, Koulla S.
Population-Based Monitoring of Emerging HIV-1 Drug Resistance on Antiretroviral Therapy and Associated Factors in a Sentinel Site in Cameroon: Low Levels of Resistance but Poor Programmatic Performance
title Population-Based Monitoring of Emerging HIV-1 Drug Resistance on Antiretroviral Therapy and Associated Factors in a Sentinel Site in Cameroon: Low Levels of Resistance but Poor Programmatic Performance
title_full Population-Based Monitoring of Emerging HIV-1 Drug Resistance on Antiretroviral Therapy and Associated Factors in a Sentinel Site in Cameroon: Low Levels of Resistance but Poor Programmatic Performance
title_fullStr Population-Based Monitoring of Emerging HIV-1 Drug Resistance on Antiretroviral Therapy and Associated Factors in a Sentinel Site in Cameroon: Low Levels of Resistance but Poor Programmatic Performance
title_full_unstemmed Population-Based Monitoring of Emerging HIV-1 Drug Resistance on Antiretroviral Therapy and Associated Factors in a Sentinel Site in Cameroon: Low Levels of Resistance but Poor Programmatic Performance
title_short Population-Based Monitoring of Emerging HIV-1 Drug Resistance on Antiretroviral Therapy and Associated Factors in a Sentinel Site in Cameroon: Low Levels of Resistance but Poor Programmatic Performance
title_sort population-based monitoring of emerging hiv-1 drug resistance on antiretroviral therapy and associated factors in a sentinel site in cameroon: low levels of resistance but poor programmatic performance
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753336/
https://www.ncbi.nlm.nih.gov/pubmed/23991142
http://dx.doi.org/10.1371/journal.pone.0072680
work_keys_str_mv AT billongsergec populationbasedmonitoringofemerginghiv1drugresistanceonantiretroviraltherapyandassociatedfactorsinasentinelsiteincameroonlowlevelsofresistancebutpoorprogrammaticperformance
AT fokamjoseph populationbasedmonitoringofemerginghiv1drugresistanceonantiretroviraltherapyandassociatedfactorsinasentinelsiteincameroonlowlevelsofresistancebutpoorprogrammaticperformance
AT aghokengavelinf populationbasedmonitoringofemerginghiv1drugresistanceonantiretroviraltherapyandassociatedfactorsinasentinelsiteincameroonlowlevelsofresistancebutpoorprogrammaticperformance
AT milengepascal populationbasedmonitoringofemerginghiv1drugresistanceonantiretroviraltherapyandassociatedfactorsinasentinelsiteincameroonlowlevelsofresistancebutpoorprogrammaticperformance
AT kembouetienne populationbasedmonitoringofemerginghiv1drugresistanceonantiretroviraltherapyandassociatedfactorsinasentinelsiteincameroonlowlevelsofresistancebutpoorprogrammaticperformance
AT abessouguieibile populationbasedmonitoringofemerginghiv1drugresistanceonantiretroviraltherapyandassociatedfactorsinasentinelsiteincameroonlowlevelsofresistancebutpoorprogrammaticperformance
AT mevaaongleneflorebeatrice populationbasedmonitoringofemerginghiv1drugresistanceonantiretroviraltherapyandassociatedfactorsinasentinelsiteincameroonlowlevelsofresistancebutpoorprogrammaticperformance
AT bissekanneczoungkanyi populationbasedmonitoringofemerginghiv1drugresistanceonantiretroviraltherapyandassociatedfactorsinasentinelsiteincameroonlowlevelsofresistancebutpoorprogrammaticperformance
AT colizzivittorio populationbasedmonitoringofemerginghiv1drugresistanceonantiretroviraltherapyandassociatedfactorsinasentinelsiteincameroonlowlevelsofresistancebutpoorprogrammaticperformance
AT mpoudieiteln populationbasedmonitoringofemerginghiv1drugresistanceonantiretroviraltherapyandassociatedfactorsinasentinelsiteincameroonlowlevelsofresistancebutpoorprogrammaticperformance
AT elatjeanboscon populationbasedmonitoringofemerginghiv1drugresistanceonantiretroviraltherapyandassociatedfactorsinasentinelsiteincameroonlowlevelsofresistancebutpoorprogrammaticperformance
AT shirokoullas populationbasedmonitoringofemerginghiv1drugresistanceonantiretroviraltherapyandassociatedfactorsinasentinelsiteincameroonlowlevelsofresistancebutpoorprogrammaticperformance